Faecal markers of gastrointestinal inflammation
暂无分享,去创建一个
[1] R. Guerrant,et al. Correlation of lactoferrin with neutrophilic inflammation in body fluids , 1995, Clinical and diagnostic laboratory immunology.
[2] J. Gisbert,et al. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. , 2009, Inflammatory bowel diseases.
[3] A. Schoepfer,et al. Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies , 2008, Inflammatory bowel diseases.
[4] L. Denson,et al. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease , 2006, Inflammatory bowel diseases.
[5] D. Martines,et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease , 2007, International Journal of Colorectal Disease.
[6] Jesmin Akter,et al. Evaluation of Faecal Occult Blood Test and Lactoferrin Latex Agglutination Test in Screening Hospitalized Patients for Diagnosing Inflammatory and Non-Inflammatory Diarrhoea in Dhaka, Bangladesh , 2008, Digestion.
[7] J. Stein,et al. Prospective evaluation of faecal neutrophil‐derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin , 2007, Alimentary pharmacology & therapeutics.
[8] A. Røseth,et al. High prevalence of NSAID enteropathy as shown by a simple faecal test , 1999, Gut.
[9] Z. Ge,et al. Relationship between fecal lactoferrin and inflammatory bowel disease , 2007, Scandinavian journal of gastroenterology.
[10] E. Husebye,et al. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm , 2001, American Journal of Gastroenterology.
[11] M. Mohiuddin,et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease , 2009, The British journal of surgery.
[12] R. Gearry,et al. Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation. , 2005, The New Zealand medical journal.
[13] A. Schoepfer,et al. Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI , 2010, The American Journal of Gastroenterology.
[14] J. Goldblum,et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. , 2004, Gastroenterology.
[15] M. Huml,et al. Evaluation of faecal calprotectin as a valuable non‐invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis , 2010, Acta paediatrica.
[16] I. Forgacs,et al. Fecal M2‐pyruvate kinase (M2‐PK): A novel marker of intestinal inflammation , 2007, Inflammatory bowel diseases.
[17] D. Foell,et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome , 2007, Gut.
[18] A. Day,et al. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children , 2008, Inflammatory bowel diseases.
[19] N. D. de Wit,et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome , 2008, Clinical chemistry and laboratory medicine.
[20] Tracy Stamboldjiev. Management of Irritable Bowel Syndrome in Primary Care , 2011 .
[21] A. Griffiths,et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response , 2010, Gut.
[22] R. Ayling. New faecal tests in gastroenterology , 2012, Annals of clinical biochemistry.
[23] A. Tursi,et al. Faecal calprotectin in colonic diverticular disease: a case–control study , 2008, International Journal of Colorectal Disease.
[24] S. Dolwani,et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology , 2004, Alimentary pharmacology & therapeutics.
[25] K. Herzig,et al. Fecal pyruvate kinase: A potential new marker for intestinal inflammation in children with inflammatory bowel disease , 2007, Scandinavian journal of gastroenterology.
[26] J. Dahlerup,et al. Fecal calprotectin: assessment of a rapid test , 2008, Scandinavian journal of clinical and laboratory investigation.
[27] Douglas W Mahoney,et al. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia , 2003, American Journal of Gastroenterology.
[28] S. Lewis,et al. Fecal dimeric M2‐pyruvate kinase (tumor M2‐PK) in the differential diagnosis of functional and organic bowel disorders , 2009, Inflammatory bowel diseases.
[29] A. Michalsen,et al. Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.
[30] R. Guerrant,et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes , 1992, Journal of clinical microbiology.
[31] A. Day,et al. Fecal S100A12: A novel noninvasive marker in children with Crohn's disease , 2006, Inflammatory bowel diseases.
[32] P. Rufo,et al. Fecal Lactoferrin Is a Sensitive and Specific Marker of Disease Activity in Children and Young Adults With Inflammatory Bowel Disease , 2007, Journal of pediatric gastroenterology and nutrition.
[33] A. Michalsen,et al. Comparison of 4 Neutrophil‐Derived Proteins in Feces As Indicators of Disease Activity in Ulcerative Colitis , 2005, Inflammatory bowel diseases.
[34] S. Bischoff,et al. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases , 2008, International Journal of Colorectal Disease.
[35] J. Stein,et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. , 2008, The American journal of medicine.
[36] J. Gisbert,et al. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[37] A. Darzi,et al. Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy , 2007, The American Journal of Gastroenterology.
[38] M. Camilleri,et al. Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation , 2003, American Journal of Gastroenterology.
[39] R. Gama,et al. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits , 2013, Annals of clinical biochemistry.
[40] C. Williams. Does the incidence of IBD increase when persons move from a low- to a high-risk area? , 2008, Inflammatory bowel diseases.
[41] A. Schoepfer,et al. Accuracy of Four Fecal Assays in the Diagnosis of Colitis , 2007, Diseases of the colon and rectum.
[42] I. Forgacs,et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.
[43] P. Brandtzaeg,et al. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. , 1985, American journal of clinical pathology.
[44] E. Eigenbrodt,et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer , 2004, British Journal of Cancer.
[45] I. Bjarnason,et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.